MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion

Clinica Terapeutica

Volumn 154, Issue 5, 2003, Pages 299-303

  Cruciani, Filippo ^a   Moramarco, A ^a   Curto, T ^a   Labate, A ^a   Recupero, V ^a   Conti, L ^b   Gandolfo, G M ^a   Balacco Gabrieli, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Factor II G20210; Factor V Leiden; MTHFR C677T; Retinal vein occlusion

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; PROTEIN C; PROTHROMBIN; VITRONECTIN; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; GROUPS BY AGE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; RETINA VEIN OCCLUSION; RISK FACTOR; ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; AGE; ALLELE; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; FEMALE; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MALE; MIDDLE AGED; MUTATION; POINT MUTATION; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGE FACTORS; ALLELES; ANALYSIS OF VARIANCE; DATA INTERPRETATION, STATISTICAL; FACTOR V; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; POINT MUTATION; PROTHROMBIN; RETINAL VEIN OCCLUSION; RISK FACTORS; SEX FACTORS;

EID: 2642581711     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alhenc-gales M, Nicaud V, Gandrille S, et al.: The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 81: 193-7, 1999
2. De Stefano V, Zappacosta B, Persichilli S, et al.: Prevalence of mild Hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol, 106(2): 564-8, 1999
3. Hessner Mj, Luhm RA, Pearson SL, et al.: Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR Thromb Haemost, 81(5): 733-38, 1999
4. Greiner K, Hafner G, et al.: Retinal vascular occlusion and deficencies in the protein C pathway Am J Ophthalmol, 128(1): 69-74, 1999
5. Greven CM, Wall EB: Peripheral retinal Neovascularization and retinal vascular occlusion asociated with actived protein C resistance. Am J Ophthalmol, 124(25): 687-9, 1997
6. Kalayci D, Gurgey A, Guven D, et al.: Factor V Leiden and prothrombin 20210A mutations in patients with central and branch retinal vein occlusion. Acta Ophthalmol Scand 77 (6): 622-4, 1999
7. Margaglione M, D'Andrea G, Colaizzo D, et al.: Coexistence of Factor V Leiden and Factor II A20210 mutations and recurrent venous Thromboembolism. Thromb Haemost 82: 1583-7, 1999
8. Kang SS, Zhou J, Wong PW, et al.: Intermediate Homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet, 43: 414-421, 1988
9. Dodson P, Westwick J, Marks G, et al.: Beta thromboglobulin and platlet factor 4 levels in retinal vein occlusion. Br. J Ophthalmol, 143-146, 1983
10. Barrai I: Introduzione alia genetica di popolazioni. Isedi, Firenze, 1980
11. Coscas G, Dhermy P: Occlusions veineuses rétiniennes. Rapport de la Soc Fr Ophtalmol. Masson, Paris, 1978
12. Glacet-Bernard A, Coscas G, Soubrane G: Les occlusions veineusese rétiniennes. Sang Thrombose Vaisseaux 10: 642-50, 1998
13. Gottlieb JL, Blice Jp, Mestichelli B, et al.: Actived protein C, Factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol, 116(5): 577-9, 1998
14. Klijtmans LAJ, Boers GHJ, Verbuggen B, et al.: Homozygous Cystationine b synthase deficency, combined with factor V Leiden or thermolabile Methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood 6: 2015-2018, 1998
15. Larsson J et al.: Actived protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 81(10): 832-4, 1997
16. Larsson J, Hillarp A, Olafdottir E et al.: Actived protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta ophthalmol Scand, 77(6): 634-7, 1999
17. Nordstrom M, Kiellstrom T: Age and cystathionine b-syntase activity in cultured fibroblast from patients with arterial and venous vascular disease. Atherosclerosis 139: 231-236, 1998
18. Blom HJ: Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinemia. Eur J pediatr, 157 (suppl 2): S131-S134, 1998
19. Balacco Gabrieli C, Bozzoni Pantaleoni F, Contestabile MT, et al.: Trattamento laser dell'edema maculare nelle trombosi venose di branca: Nostre esperienze. Atti del VIII Congresso della S.I.L.O-pp13-20-Cortina D'Ampezzo, 16-18 Gen. 1992
20. Balacco Gabrieli C, Cruciani F, Apolloni R, et al.: Le occlusioni venose retiniche nelle malattie sistemiche. Atti del I Meeting delle Società di Oftalmologia del Centre Italia, Maggio 1994
21. Cattaneo M: Hyperhomocysteinemia, Atherosclerosis and Thrombosis Thromb Haemost, 81: 165-76, 1999
22. De Stefano V, Zappacosta B, Persichilli S, et al.: Prevalence of mild Hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol, 106(2): 564-8, 1999
23. Gris JC, Quère I, Monpeyroux F, et al.: Case-control of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent. Thromb haemost, 81: 891-99, 1999
24. Guven D, Saynalp N, Kalayci D, et al.: Risk factors in central retinal vein occlusion and actived protein C resistance. Eur J Ophthalmol, 9(1): 43-8, 1999
25. Sanborn G, et al.: Actived protein C resistance in central retinal vein occlusion. Br J Ophthalmol, 80(12): 1116, 1996
26. Selhub J: Homocysteine metabolism. Annu Rev Nutr, 19: 217-46, 1999
27. Spagnolo BV, Nashrallah FP: Bilateral retinal vein occlusion associated with factor V Leiden mutation. Retina 18(4): 377-8, 1998
28. Tekeli O, et al.: Protein C, protein S and antitrombin III in retinal vein occlusion. Acta Ophthalmol Scand, 77(6): 628-30, 1999
29. Van der Molen Ef, Hipakka MJ, Van Lith-Zanders H, et al.: Homocysteine metabolism in endothelial cells of a patient homozygous for cystationine b(cs) deficency. Thromb Haemost, 78: 827-33, 1997
30. Williamson TH et al.: Blood viscosity, coagulation, and actived protein C resistance in central retinal vein occlusion: a population control study. Br J Ophthalmol, 80(3): 203-8, 1996
31. Yesim F, Demirici K, Guney DB: Prevalence of factor V Leiden in patients with retinal vein occlusion. Acta Ophthalmol Scand, 77(6): 631-3, 1996
32. Zwierzina WD, Knuz F, Miller K: Retinal vascular occlusion in antithrombin III deficency. Klin Monatsbl Augenheilkd 187(6): 534-6, 1985